Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma

HCC incidence is still growing in Western countries.[1,2] Tumor development is frequently related to liver damage, typically caused by cirrhosis. While curative treatments (transplantation, resection, percutaneous destruction) can be proposed for small tumors, about two thirds of patients cannot receive such treatments.[3]

Source: Journal of Hepatology - May 20, 2019 Category: Gastroenterology Authors: Jean-Louis Jouve, Thierry Lecomte, Olivier Bouch é, Emilie Barbier, Faiza Khemissa Akouz, Ghassan Riachi, Eric Nguyen Khac, Isabelle Ollivier-Hourmand, Maryline Debette-Gratien, Roger Faroux, Anne-Laure Villing, Julien Vergniol, Jean-François Ramee, Jea Source Type: research